$12.3 Million is the total value of ABG-WTT Global Life Science Capital Partners GP Ltd's 3 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | Rapid Micro Biosystems Inc | $7,050,000 | – | 1,038,296 | +100.0% | 57.23% | – | |
| MDVL | MEDAVAIL HOLDINGS INC | $3,774,000 | -30.6% | 3,885,951 | 0.0% | 30.64% | -58.5% | |
| LUNG | PULMONX CORP | $1,494,000 | -22.6% | 60,204 | 0.0% | 12.13% | -53.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MEDAVAIL HOLDINGS INC | 12 | Q3 2023 | 92.0% |
| PULMONX CORP | 12 | Q3 2023 | 49.0% |
| RAPID MICRO BIOSYSTEMS INC | 7 | Q3 2023 | 57.2% |
| RAYZEBIO INC | 1 | Q3 2023 | 83.0% |
View ABG-WTT Global Life Science Capital Partners GP Ltd's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-21 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-03-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View ABG-WTT Global Life Science Capital Partners GP Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.